CervoMed plans neflamapimod 100 mg twice-daily regimen for future trials

The company said Phase 1 results for a new 50 mg tablet support steadier drug levels and twice-daily dosing. FDA lifted a prior plasma exposure cap, removing a constraint on dose escalation in upcoming studies.